Pelayanan Kefarmasian Pada Pasien Imunosupresif Sebagai Tindakan Preventif di Masa Pandemi COVID-19

ZAFIRA ZAHRAH, YUNISTYA DWI CAHYANI

Abstrak


Virus SARS-CoV-2 atau yang disebut sebagai COVID-19 saat ini telah menyebar ke lebih dari 200 negara di seluruh dunia, dan dinyatakan sebagai pandemi oleh World Health Organization (WHO) pada 11 Maret 2020. Virus terbukti sangat mematikan bagi orang dewasa (terutama usia lanjut) dan orang-orang dengan kondisi medis tertentu, diantaranya pasien imunosupresif. Apoteker sebagai tenaga medis yang mengenal obat sangat baik dibutuhkan peranannya dalam melakukan pencegahan dan pemantauan untuk meminimalkan infeksi lanjutan pada pasien imunosupresif. Artikel review ini bertujuan untuk menggali dan mengevaluasi pelayanan kefarmasian yang harus dilakukan terhadap kelompok pasien imunosupresif selama masa pandemi. Penelusuran referensi dilakukan melalui database Google Scholar dengan menggunakan kata kunci “Coronavirus and immunocompromised”, “SARS-CoV-2 and immunosuppressant drugs”, “COVID-19 and immunosuppressive patients”, “non-pharmacologic treatment in pandemic COVID-19” dan “Pharmacist role in pandemic COVID-19”. Hasil penelusuran menunjukkan bahwa tidak ada perbedaan protokol pelayanan kefarmasian yang signifikan pada kasus pasien imunosupresif yang disebabkan oleh penyakit HIV dan penggunaan agen sitostatika serta imunosupresan, di mana seluruh pasien harus tetap mengonsumsi obatnya dalam rangka membangun sistem imun yang stabil dan mengikuti anjuran pemerintah untuk meminimalisasi kontak dengan masyarakat agar tidak terpapar virus korona.


Teks Lengkap:

PDF

Referensi


BMJ Best Practice. Overview of Coronaviruses [cited 2020 April 28]. Available from: https://bestpractice.bmj.com/topics/en-gb/3000165

World Health Organization. Updated WHO advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV [cited 2020 April 28]. Available from: https://www.who.int/ith/2020-24-01-outbreak-of-Pneumonia-caused-by-new-coronavirus/en/

World Health Organization. Coronavirus disease (COVID-2019) situation reports [cited 2020 April 28]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

World Health Organization Indonesia. Coronavirus Disease 2019 (COVID-19) World Health Situation Report – 5 [cited 2020 April 28]. Available from: https://www.who.int/docs/default-source/searo/indonesia/covid19/who-situation-report-5.pdf?sfvrsn=f1d00104_2

Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience [Internet]. 2020;19 [cited 2020 April 28]. Available from: https://doi.org/10.1007/s11357-020-00186-0

Pusat Data dan Informasi Kementerian Kesehatan RI. 2018. Situasi Umum HIV/AIDS dan Tes HIV. Jakarta: Kementerian Kesehatan RI.

BPJS Kesehatan. Media Internal BPJS Kesehatan. Jakarta: BPJS Kesehatan; 2019. Report No.: 68.

Hughes, U. Pattern of Clinical Presentations in Immunocompromised Patient. In: Metodiev, K. Immunodeficiency [Internet]. London: InTechOpen; 2012 [cited 2020 May 07]. Available from: https://doi.org/10.5772/51519

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020 Mar 1;21(3):335-7.

Morey JN, Boggero IA, Scott AB, Segerstrom SC. Current directions in stress and human immune function. Current opinion in psychology. 2015 Oct 1; 5:13-17.

Ivulich S, Snell G. Long-term management of elderly patients taking immunosuppressive medications. AJGP. 2020; 49(3): 100-111.

Bays AM, Gardner G. Pharmacologic therapies for rheumatologic and autoimmune conditions. Med Clin North Am. 2016;100(4):719–31.

Biehl AJ, Katz JD. Pharmacotherapy pearls for the geriatrician: Focus on oral disease-modifying antirheumatic drugs including newer agents. Clin Geriatr Med. 2017;33(1):1–15.

Sammut L, Wallis D, Holroyd C. Progressive multifocal leukoencephalopathy associated with infliximab. J R Coll Physicians Edinb. 2016;46(3):163–65.

Su YC, Lin PC, Yu HC, Wu CC. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. Eur J Gastroenterol Hepatol. 2018;30(8):925–29.

Weir MR, Salzberg DJ. Management of hypertension in the transplant patient. J Am Soc Hypertens. 2011;5(5):425–32.

Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Therapeutic advances in chronic disease. 2013 Jul;4(4):167-85.

Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Buchar). 2011;6(4):330-336.

Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/ immunosuppressant use in dermatology. J Am Acad Dermatol [Internet]. 2020;82(5):e173–5. Available from: https://doi.org/10.1016/j.jaad.2020.03.046

The Renal Association. Guidance for Clinicians with Patients Receiving Immunosuppression Treatment for Autoimmune Conditions of their Native Kidneys During Covid-19 [cited 2020 May 3]. Available from: https://renal.org/guidance-clinicians-patients-receiving-immunosuppression-treatment-autoimmune-conditions-native-kidneys-covid-19/

Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev. 2013;9(1):15-19.

Del Pino-Sedeño T, Trujillo-Martín MM, Ruiz-Irastorza G, Cuellar-Pompa L, de Pascual-Medina AM, Serrano-Aguilar P; Spanish Systemic Lupus Erythematosus CPG Development Group. Effectiveness of nonpharmacologic interventions for decreasing fatigue in adults with systemic lupus erythematosus: a systemic review. Arthritis Care Res (Hoboken). 2016; 68(1):141-148.

Sharif K, Watad A, Bragazzi NL, Lichtbroun M, Amital H, Shoenfeld Y. Physical activity and autoimmune diseases: Get moving and manage the disease. Autoimmunity Reviews. 2018;17(1):53-72.




DOI: https://doi.org/10.24198/farmaka.v18i2.27362

DOI (PDF): https://doi.org/10.24198/farmaka.v18i2.27362.g14724

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved